Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia

Wyeth is now a wholly owned subsidiary of Pfizer

Overview

The primary objectives are a) to establish the maximum tolerated dose of gemtuzumab ozogamicin in combination with cytarabine and b) to assess the safety of gemtuzumab ozogamicin when given concurrently with cytarabine.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

Acute Myeloid Leukemia

Interventions

Gemtuzumab OzogamicinDRUG

cytarabine.DRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Morphologic diagnosis of AML from bone marrow aspirate and biopsy * Flow cytometry, performed at the study site, must demonstrate that the patient has AML that is CD33+, based on local laboratory criteria * Age 18 years or older for relapsed or refractory patients for Phase I of this study Exclusion Criteria: * Patients with de novo AML of the M3 subtype * AML following an antecedent hematologic disorder (myelodysplasia or myeloproliferation) of \> 2 months duration * AML secondary to exposure to chemotherapy or radiation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.